Neurology CME Courses, Case Studies | Online Neurologic CME

Neurology CME Courses

Neurology CME/CE Courses

myCMEYour search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.


Featured Courses

OFF to ON: Strategies to Manage OFF Episodes in Patients with Parkinson’s disease

OFF to ON: Strategies to Manage OFF Episodes in Patients with Parkinson’s disease | myCME

AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s)
The activity will review information that community neurologists need to know about Parkinson’s disease (PD) motor fluctuations, including clinical manifestations, the role of gut absorption of levodopa on symptom patterns, the variety of established and newer therapeutic management strategies, and the need to involve patients in shared decision-making.
2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era

2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era | myCME

AMA PRA Category 1 Credit(s)TM
Although the multifactorial causes of multiple sclerosis (MS) are not known, an improved understanding of the neuroimmunologic pathogenesis has led to the development of a wide variety of disease-modifying treatments (DMTs). While there is no cure for MS, these treatments can reduce disease activity and delay MS progression and disability.
Racial and Genetic Implications for MS Treatment Selection

Racial and Genetic Implications for MS Treatment Selection

AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s), CE for Pharmacists, AAPA Category I CME credit
This online session will explore differences in the prevalence and incidence of Multiple Sclerosis based on gender and race, as well as the implications for treatment selection and management of side effects.
Rethinking Routines in Multiple Sclerosis Management: What the Future Holds for DMTs and Cognitive Assessment Strategies

Rethinking Routines in Multiple Sclerosis Management | myCME

AMA PRA Category 1 Credit(s)TM, CE for Pharmacists, CNE Contact Hour(s)
This CME Outfitters webcast will feature an expert panel discussion that focuses on the efficacy and safety of recently approved DMTs, implementing cognitive assessment into routine monitoring for patients with MS, and emerging data on the effects of MS therapies on cognition.
When and How to Switch Therapies in MS: Neurology Guideline Implementation and Expert Recommendation

When and How to Switch Therapies in MS: Neurology Guideline Implementation and Expert Recommendation | myCME

AMA PRA Category 1 Credit(s)TM
Medications such as immunomodulatory and immunosuppressive disease-modifying therapies (DMTs) can delay this damage and slow the resulting progressive phase, thus helping maintain quality of life for patients with Multiple Sclerosis. To make an informed decision, clinicians need to understand the rationale behind medication choices and the risks and benefits of DMTs available.
Safe and Effective Use of MS Disease-Modifying Therapies During the COVID-19 Crisis

Safe and Effective Use of MS Disease-Modifying Therapies During the COVID-19 Crisis | myCME

AMA PRA Category 1 Credit(s)TM
As coronavirus disease 19 (COVID-19) has become a worldwide issue, being declared a pandemic by the World Health Organization, it affects many aspects of healthcare. Specifically, many patients with multiple sclerosis (MS) take medications that alter or suppress their immune system. Rightly, they and their treatment team are concerned about the safest, but also most effective treatment strategy that considers both MS and the risk of COVID-19.
Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management

Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management | myCME

AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s), CE for Pharmacists
This activity provides an overview of the role of the innate and adaptive immune systems in the development and progression of multiple sclerosis (MS), while exploring the therapeutic implications of immune dysfunction. MS immunotherapies are reviewed, with a focus on their mechanisms of action and immune-related toxicities. Patient case studies are included to illustrate considerations in the selection and sequencing of therapy and the management of immune-related toxicities.
Next-Generation S1P Modulators in MS Management

Next-Generation S1P Modulators: Clinical Implications of Higher Selectivity in MS Management | myCME

AMA PRA Category 1 Credit(s)TM, ANCC Contact Hour(s), CE for Pharmacists
Multiple sclerosis (MS) management requires balancing the benefits of medications aimed at inhibiting inflammation and immunosuppression or immunomodulation against the risks of serious adverse effects and other drawbacks, such as the inconvenience and discomfort of infusions or injections. In this roundtable discussion, 2 experts in MS management review current and investigational treatments with a focus on newer sphingosine 1-phosphate (S1P) receptor modulators.
Optimizing Patient Outcomes in Myasthenia Gravis With Timely Diagnosis and Targeted Therapy

Optimizing Patient Outcomes in Myasthenia Gravis With Timely Diagnosis and Targeted Therapy | myCME

AMA PRA Category 1 Credit(s)TM
In this first myCME™ Expert Perspectives activity in a series of 2 programs, clinical experts in the management of patients with myasthenia gravis (MG) discuss the scope of the problem of the disease and strategies to promote timely and appropriate diagnosis. Evidence-based first-line MG treatment strategies will be reviewed, as will the potential limitations of these therapies.
Optimizing Management of Myasthenia Gravis With Novel Targeted Therapy

Optimizing Management of Myasthenia Gravis With Novel Targeted Therapy | myCME

AMA PRA Category 1 Credit(s)TM
During this myCME ™ Expert Perspectives roundtable discussion, 3 distinguished faculty discuss new understandings of the immunologic processes involved in the development of myasthenia gravis (MG,) the novel agents that target these processes, and the most recent clinical evidence for efficacy and safety. The faculty will also discuss the potential advantages of newer agents over conventional MG agents.
BRAINWeekEnd: A 3-Part Review Addressing Management and Treatment Options for Relapsing Remitting MS, Schizophrenia, and Parkinson’s Disease

BRAINWeekEnd: A 3-Part Review Addressing Management and Treatment Options for Relapsing Remitting MS, Schizophrenia, and Parkinson’s Disease | myCME

AMA PRA Category 1 Credit(s)TM, ANCC Contact Hour(s), AANP Contact Hour(s), CE for Pharmacists
A rising geriatric population, increased life expectancy, and the anticipated launch of novel molecules are driving the need for continuing medical education for clinicians treating neurological disorders. This BRAINWeek Highlights activity presents three timely and relevant presentations focused on the most commonly diagnosed CNS conditions.

Click for More Neurology Courses

Next hm-section-front in Neurology CME Courses